FOXA1 and neoplasm: We revealed TFs whose expression is linked to a large number of tumor-specific enhancers and further characterized selected TFs for each tumor type (e.g., BRCA: GATA3, FOXA1, ESR1, PRAD: HOXC6, DLX1, KIRC: ZNF395) and for specific tumor subgroups.